> If anyone doubted Andrew Witty's professed faith in emerging markets, those doubts can be put to rest. The incoming GlaxoSmithKline CEO lured Eli Lilly's Abbas Hussein to spearhead a new unit
Management consultant Dr. David A. Shaywitz has joined with Dr. Dennis A. Ausiello, the physician-in-chief of Massachusetts General Hospital and a director at Pfizer, to deliver a rebuttal to a small
Pfizer is back at the negotiating table with the Nigerian state of Kano in an attempt to finally settle claims about a meningitis drug trial the government contends was conducted illegally. The
> GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company.
A new guerilla marketing campaign for over-the-counter Zyrtec proves one thing: If you want attention in the blogosphere, post a few drug ads on telephone poles. They're flyers designed to appear
Last week, we reported Â on Big Pharma's march on the capital in support of new off-label marketing rules.
Pfizer shares hit a 10-year low yesterday. And who can blame investors who sold, considering the Eeyore tone Wall Street analysts took after the drugmaker announced its
Call it the backlash against the backlash. In the wake of the recent
Commonly used incontinence drugs may cause memory problems in older people, according to a new study funded by the National Institute on Aging. "Our message is to be careful when using these
Review the research on epilepsy meds, and what do you find? Neurontin (gabapentin), is no better than placebo for bipolar disorder, according to the Prescribing for Better Outcomes center at the